|
|
|
|
|
Chlorotrianisene
drug data and news
Chlorotrianisene drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Chlorotrianisene | ||
| Brand Names/Synonyms | Anisene; CCRIS 4769; CTA; Chloortrianisestrol; Chlorestrolo; Chlorotrianisene; Chlorotrianisene [Ban:Inn]; Chlorotrianisenum [Inn-Latin]; Chlorotrianisine; Chlorotrianizen; Chlorotrisin; Chlortrianisen; Chlortrianisene; Chlortrianisenum; Chlortrianisestrol; Chlortrianisoestrolum; Chlortrianizen; Clorestrolo; Clorotrianisene [Dcit]; Clorotrianiseno [Inn-Spanish]; Clorotrisin; HSDB 3302; Hormonisene; Khlortrianizen; Merbentul; Metace; NSC-10108; Rianil; Tace; Tace-Fn; Trianisestrol | ||
| Indication | Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Chlorotrianisene is a nonsteroidal synthetic estrogen. After menopause, when the body no longer produces estrogen, chlorotrianisene is used as a simple replacement of estrogen. The estrogen-stimulated endometrium may bleed within 48-72 hours after discontinuance of estrogen therapy. Paradoxically, prolonged estrogen therapy may cause shrinkage of the endometrium and an increase in size of the myometrium. Estrogens have a weak anabolic effect and may cause sodium retention with associated fluid retention and edema. Estrogens may also decrease elevated blood cholesterol and phospholipid concentrations. Estrogens affect bone by increasing calcium deposition and accelerating epiphyseal closure, following initial growth stimulation. During the preovulatory or nonovulatory phase of the menstrual cycle, estrogen is the principal determinant in the onset of menstruation. A decline of estrogenic activity at the end of the menstrual cycle also may induce menstruation; however, the cessation of progesterone secretion is the most important factor during the mature ovulatory phase of the menstrual cycle. The benefit derived from estrogen therapy in the prevention of postpartum breast engorgement must be carefully weighed against the potential increased risk of puerperal thromboembolism associated with the use of large doses of estrogens. | ||
| Mechanism Of Action | Chlorotrianisene binds to the estrogen receptor on various estrogen receptor bearing cells. Target cells include cells in the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. | ||
| Chlorotrianisene News (When available) |
| ||
| Dosage Forms | CAPSULE (12 mg) | ||
| Drug_Category | Antineoplastic Agents; Estrogens, Non-Steroidal; ATC:G03CA06 | ||
| Absorption | Absorption following oral administration is rapid. | ||
| Interactions |
Interactions for Chlorotrianisene: Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin. | ||
| Toxicity | Acute overdosage of large doses of oral contraceptives in chidren reportedly produces almost no toxicity except nausea and vomiting. Acute overdosage of estrogens may cause nausea, and withdrawal bleeding may occur in females. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 1-[2-chloro-1,2-bis(4-methoxyphenyl)-ethenyl]-4-methoxy-benzene | ||
| Chemical Formula | C23H21ClO3 | ||
| Molecular Weight | 380.864 g/mol | ||
| Smiles String | COC1=CC=C(C=C1)C(=C(C2=CC=C(C=C2)OC)Cl)C3=CC=C(C=C3)OC | ||
| Melting Point | 115 °C | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 6.7 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Metabolized principally in the liver, although the kidneys, gonads, and muscle tissues may be involved to some extent. The metabolic fate of the synthetic estrogens has not been fully elucidated. | ||
| Half Life | Not Available | ||
| Protein Binding [%] | 50-80% | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | Not Available | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00715 | ||
| CAS Registry Number | 569-57-3 | ||
| KEGG Compound ID | C06904 | ||
| PubChem ID | SID:9121 | ||
| PharmGKB ID | PA448955 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |